Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescribed drugs’ (INO) inventory in 2025. Inventory forecasts are primarily based on numerous components corresponding to the corporate’s monetary efficiency, trade developments, and total financial circumstances.
Inovio is a clinical-stage biotechnology firm targeted on growing and commercializing DNA-based immunotherapies for infectious illnesses and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s presently in Part 3 scientific trials. Inovio additionally has a pipeline of different DNA-based vaccines in growth for numerous infectious illnesses and most cancers indications.
